How I Treat Ph+ Acute Lymphoblastic Leukemia: Controversial Treatment Options
Description
The treatment of Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia has significantly changed with the advent of tyrosine kinase inhibitor (TKI) therapy. This talk will review: (1) choice of TKI therapy in the upfront setting; (2) the role of allogeneic hematopoietic stem cell transplant in CR1; and (3) novel approaches being evaluated in the “frail” patient.
Presenters
- Anjali Advani
Pricing
| Member Type | Price |
|---|---|
| List Price | $30.00 |
| Active, International, Emeritus, and Honorary Members | $20.00 |
| Associate, International Associate, Student, and Resident Members | $20.00 |
ASH Meeting on Hematologic Malignancies
Hear the latest developments in clinical care, and get answers to your most challenging patient care questions.
Learn more
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
Copyright © 2021 by American Society of Hematology